Ilex Medical
Ilex Medical Ltd provides healthcare technological solutions in Israel, South Africa, and internationally. The company offers microbiology, chemistry, molecular biology, immunochemistry, and blood banking solutions. It also offers coagulation, hematology, blood gases, bilirubin, biomarkers, fertility, cellular medicine occult blood, and calprotectin services, as well as provides LIS, urine micros… Read more
Ilex Medical (ILX) - Total Liabilities
Latest total liabilities as of June 2025: ILA286.90 Million ILA
Based on the latest financial reports, Ilex Medical (ILX) has total liabilities worth ILA286.90 Million ILA as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ilex Medical - Total Liabilities Trend (2008–2024)
This chart illustrates how Ilex Medical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ilex Medical Competitors by Total Liabilities
The table below lists competitors of Ilex Medical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tidewater Midstream and Infrastructure Ltd
PINK:TWMIF
|
USA | $635.21 Million |
|
DO & CO
BE:DOQ
|
Germany | €881.57 Million |
|
Dotz SA
SA:DOTZ3
|
Brazil | R$472.60 Million |
|
WestMountain Gold Inc
PINK:WMTN
|
USA | $8.17 Million |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
India | ₹531.88 Million |
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
India | ₹2.21 Billion |
|
Wawasan Dengkil Holdings Berhad
KLSE:0347
|
Malaysia | RM126.89 Million |
|
Jourdan Resources Inc
PINK:JORFF
|
USA | $222.08K |
Liability Composition Analysis (2008–2024)
This chart breaks down Ilex Medical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ilex Medical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ilex Medical (2008–2024)
The table below shows the annual total liabilities of Ilex Medical from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA347.58 Million | -11.47% |
| 2023-12-31 | ILA392.61 Million | +37.24% |
| 2022-12-31 | ILA286.08 Million | -4.48% |
| 2021-12-31 | ILA299.49 Million | -10.79% |
| 2020-12-31 | ILA335.71 Million | +29.93% |
| 2019-12-31 | ILA258.38 Million | +7.71% |
| 2018-12-31 | ILA239.89 Million | +9.66% |
| 2017-12-31 | ILA218.77 Million | -9.99% |
| 2016-12-31 | ILA243.05 Million | -4.92% |
| 2015-12-31 | ILA255.61 Million | -15.34% |
| 2014-12-31 | ILA301.94 Million | -5.69% |
| 2013-12-31 | ILA320.16 Million | -6.04% |
| 2012-12-31 | ILA340.74 Million | -15.71% |
| 2011-12-31 | ILA404.25 Million | +470.83% |
| 2010-12-31 | ILA70.82 Million | +7.96% |
| 2009-12-31 | ILA65.60 Million | +8.08% |
| 2008-12-31 | ILA60.69 Million | -- |